Publications:105
Kirk Campbell, MD
About Me
Dr. Kirk Campbell is the Irene and Dr. Arthur M. Fishberg Professor of Medicine and Professor of Pharmacological Sciences and inaugural Director of the Mount Sinai Center for Kidney Disease Innovation. The Center integrates multidisciplinary glomerular disease, polycystic kidney disease, onco-nephrology and diabetic kidney disease (DKD) clinical programs into a translational research framework. The goal is to leverage state-of-the-art genomic, bioinformatics and molecular phenotyping technology to identify novel therapeutic targets for drug discovery and biomarker validation while expanding patient registry, biobanking, and clinical trial opportunities. These efforts enhance early detection, prevention, and treatment of kidney disease and its complications while expanding Mount Sinai's precision medicine capabilities.
Dr. Campbell received his medical degree from the University of Connecticut. He completed his internal medicine residency at Yale University before pursuing clinical nephrology and postdoctoral research training at Mount Sinai. Dr. Campbell is the President-elect of the National Kidney Foundation, former President of the New York Society of Nephrology, and a member of the Board of Directors of the Nephcure Foundation. He is the recipient of a Distinguished Leader Award from the American Society of Nephrology ,and an elected member of the American Society for Clinical Investigation. Additionally, Dr. Campbell is an active member of the editorial boards of American Journal of Kidney Disease, Kidney360, Kidney International, Frontiers in Medicine and the American Journal of Physiology – Renal Physiology.
Dr. Campbell is the principal investigator (PI) of Mount Sinai’s Kidney Precision Project Recruitment Site, an NIH-funded initiative to identify new markers and treatment targets for personalized, effective, and safe treatments for kidney diseases. He has been awarded a Harrington Discovery Institute Scholar Innovator grant to advance the development of a promising therapeutic intervention for proteinuric kidney disease.
Language
English
Position
ADJUNCT PROFESSOR | Medicine, Nephrology
Multi-Disciplinary Training Areas
Development Regeneration and Stem Cells [DRS], Disease Mechanisms and Therapeutics (DMT)
Video
Research
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure. Primary and secondary pathogenic processes affecting podocytes account for 90% of end-stage kidney disease at a cost of 20 billion dollars per year in the US. A reduction in podocyte number (podocytopenia) directly correlates with the progression of several proteinuric kidney diseases including focal segmental glomerulosclerosis (FSGS), IgA nephropathy and diabetic nephropathy. Despite significant advances in the characterization of the molecular architecture of podocytes, the mechanisms underlying their survival, injury and loss remain poorly understood. Validated therapeutic targets are scarce and there are currently no podocyte-specific drugs commercially available. The overall goal of our research program is to enhance the pipeline of putative therapeutic targets available to tackle human glomerular disease by elucidating the details and functional significance of key signaling pathways that regulate podocyte injury and survival. We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression. Please go to The Campbell Laboratory at https://campbell-lab.org/
Publications
Selected Publications
- A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. Richard Lafayette, Sean J. Barbour, Robert M. Brenner, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Vivekanand Jha, Beom Seok Kim, Adrian Liew, Bart Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K.S. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimir Tesař, Hernán Trimarchi, Xuelian Wei, Hong Zhang, Jonathan Barratt. New England Journal of Medicine
- Case Series of Histopathological Findings in Chronic Kidney Disease: Insights From the Kidney Precision Medicine Project. Christine P. Limonte, Stephanie Aw, Charles E. Alpers, Laura Barisoni, Brooke Berry, Frank C. Brosius, Kirk N. Campbell, Leal C. Herlitz, Zoltan Laszik, Gearoid McMahon, Amy Mottl, Patrick Nachman, Yunbi Nam, Emilio E. Poggio, Parmjeet S. Randhawa, Sylvia E. Rosas, Isaac E. Stillman, Jonathan J. Taliercio, Jose Torrealba, Katherine Tuttle, Miguel Vazquez, Ian H. de Boer, Joel Henderson. Kidney Medicine
- Immunoglobulin A Nephropathy: New Treatment Options. Arun Rajasekaran, Dana V. Rizk, Kirk N. Campbell. Annual Review of Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Campbell during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Board Service
- National Kidney Foundation
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Access for Life
- Travere (Formerly Retrophin)
- Calliditas Pharmaceuticals
- Sanofi US Services Inc.
- Chinook Therapeutics
- Medscape
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.